Worth reading
72In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
18.8
% (percentage change in quarterly net income attributable to owners of the parent for the cumulative second quarter)Wording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending March 2027 · Cumulative second quarter and full yearPrevious forecast published 12 May 2026Net Sales—→—million yen
—
Operating profit—→—million yen
—
Ordinary income—→—million yen
—
Profit attributable to owners of the parent—→—million yen
—
Net income per share—→—yen and sen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
Sales and profits are expected to exceed the previous forecasts because market conditions for allyl ethers temporarily rose sharply in the first quarter, partly due to the situation in the Middle East, the yen has remained weaker than assumed against foreign currencies, and sales of healthcare-related products have remained firm.
Previous-period resultsCumulative second quarter (second quarter of the fiscal year ended March 2026): sales ¥48,832 million, operating profit ¥8,111 million, ordinary profit ¥8,910 million, quarterly net income attributable to owners of the parent ¥6,755 million, and quarterly earnings per share ¥53.74. Full year (fiscal year ended March 2026): sales ¥99,961 million, operating profit ¥17,634 million, ordinary profit ¥19,608 million, net income attributable to owners of the parent ¥15,460 million, and earnings per share ¥123.96.
Dividend forecast revisionThe second-quarter-end dividend was increased from ¥14 to ¥15, the year-end dividend from ¥14 to ¥15, and the annual dividend from ¥28 to ¥30.
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Cumulative second quarter 52,000; full year 106,000 → Cumulative second quarter 54,000; full year 108,000（Cumulative second quarter 3.8%; full year 1.9%） |
| Operating profit | Cumulative second quarter 8,800; full year 19,000 → Cumulative second quarter 10,300; full year 20,500（Cumulative second quarter 17.0%; full year 7.9%） |
| Ordinary income | Cumulative second quarter 9,500; full year 20,400 → Cumulative second quarter 11,200; full year 22,100（Cumulative second quarter 17.9%; full year 8.3%） |
| Profit attributable to owners of the parent | Cumulative second quarter 6,400; full year 13,600 → Cumulative second quarter 7,600; full year 14,800（Cumulative second quarter 18.8%; full year 8.8%） |
| Net income per share | Cumulative second quarter 52.10; full year 110.70 → Cumulative second quarter 62.40; full year 121.74（Cumulative second quarter —; full year —） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Cumulative second quarter and full year |
| Publication date of previous forecast | 12 May 2026 |
| Previous-period results | Cumulative second quarter (second quarter of the fiscal year ended March 2026): sales ¥48,832 million, operating profit ¥8,111 million, ordinary profit ¥8,910 million, quarterly net income attributable to owners of the parent ¥6,755 million, and quarterly earnings per share ¥53.74. Full year (fiscal year ended March 2026): sales ¥99,961 million, operating profit ¥17,634 million, ordinary profit ¥19,608 million, net income attributable to owners of the parent ¥15,460 million, and earnings per share ¥123.96. |
| Reason for the revision | Sales and profits are expected to exceed the previous forecasts because market conditions for allyl ethers temporarily rose sharply in the first quarter, partly due to the situation in the Middle East, the yen has remained weaker than assumed against foreign currencies, and sales of healthcare-related products have remained firm. |
| Dividend forecast revision | The second-quarter-end dividend was increased from ¥14 to ¥15, the year-end dividend from ¥14 to ¥15, and the annual dividend from ¥28 to ¥30. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
Details and amount of extraordinary loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Sales and profits are expected to exceed the previous forecasts because market conditions for allyl ethers temporarily rose sharply in the first quarter, partly due to the situation in the Middle East, the yen has remained weaker than assumed against foreign currencies, and sales of healthcare-related products have remained firm.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.